AN2 Therapeutics

Historical price data

AN2 Therapeutics is a public biotech company focused on discovering and developing novel boron-based small molecule therapeutics for serious infectious diseases with high unmet need. Its most advanced candidate, AN2-502998, is an oral therapy in Phase 2/3 development for chronic Chagas disease, a life-threatening parasitic infection. The company's strategy leverages a proven boron chemistry platform, pioneered at Anacor, to create potent and selective inhibitors against challenging targets, with a pipeline that also includes programs for melioidosis and oncology. AN2 is led by industry veterans with a strong track record in neglected disease drug development and partnership building.

A proprietary boron chemistry platform enabling the discovery of novel small molecule therapeutics through reversible covalent binding, allowing for potent and selective inhibition of challenging biological targets.

In Chagas disease, competition is primarily against decades-old, poorly tolerated generics, giving AN2 a potential monopoly with a successful novel therapy. For melioidosis and NTM, the competitive fields are sparse, with no specifically approved therapies, though AN2 must still demonstrate superior efficacy and safety against repurposed standard-of-care antibiotics.